Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Non-Hodgkin 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Plasma Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphoid 1Leukemia, Large Granular Lymphocytic 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 165fludarabine phosphate 110Peripheral Blood Stem Cell Transplantation 94Mycophenolic Acid 88Whole-Body Irradiation 81Etoposide 81Tacrolimus 73Busulfan 68Melphalan 67Filgrastim 66fludarabine 62Radiotherapy 56Doxorubicin 54Cyclosporine 54Rituximab 50Brentuximab Vedotin 48Antilymphocyte Serum 47Granulocyte Colony-Stimulating Factor 42Vinblastine 41Methotrexate 38Dacarbazine 37Cytarabine 35Gemcitabine 34Nivolumab 30Bleomycin 29Carmustine 28Vincristine 25Prednisone 25Sirolimus 24Bendamustine Hydrochloride 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hodgkin Disease × duvelisib × Clear all
NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
14 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡